Advertisement
GSK vs JNJ
Which Stock Would AI Choose? GSK plc (GSK) vs. Johnson & Johnson (JNJ) Stock Comparison
Key Takeaways
- GSK is a UK-based biopharma focused on Specialty Medicines, Vaccines, and General Medicines, while JNJ spans both Innovative Medicine and Medical Technology, making them differently diversified healthcare plays.
- GSK is executing a growth-and-efficiency pivot under new leadership, targeting over £40 billion in sales by 2031, while JNJ is replacing blockbuster STELARA revenue with newer oncology and immunology franchises.
- GSK's key risk is the approaching patent expiry of its HIV drug dolutegravir (2028–2030), whereas JNJ faces slower MedTech growth, litigation overhangs, and biosimilar competition.
- Both stocks have rallied over the past year, but JNJ now trades at a higher earnings multiple, leaving less room for error relative to GSK's more modest valuation.
- For further detail, readers can explore GSK Major News and GSK Today's Price Move, as well as JNJ Major News and JNJ Today's Price Move.
- To see how AI-driven strategies are positioning across the market, explore the curated Trending AI Robots section.
Introduction
GSK and Johnson & Johnson are two of the world's most recognizable healthcare names, yet they occupy different corners of the sector. GSK is a pure-play biopharmaceutical company centered on vaccines and specialty medicines, while Johnson & Johnson combines pharmaceutical leadership with a large medical device business. Comparing them offers a useful lens on how two diversified healthcare giants are navigating patent expirations, shifting sentiment, and evolving growth strategies. This stock comparison is relevant for long-term investors evaluating defensive healthcare exposure, as well as active traders tracking relative performance and market positioning across large-cap healthcare names.
GSK Overview and Recent Performance
GSK is a UK-based biopharmaceutical company whose business is organized around Specialty Medicines, Vaccines, and General Medicines. Recent weeks have been defined by a leadership transition, with new CEO Luke Miels taking over at the start of the year, and by a sharper focus on execution and research and development. In recent quarters, GSK has reported steady Specialty Medicines growth, led by HIV, oncology, and respiratory, while General Medicines has declined. Management has reaffirmed 2026 guidance for 3%–5% sales growth and 7%–9% core earnings-per-share growth, and has launched a cost-savings program targeting roughly £1.9 billion in annual savings by 2029. Sentiment has been mixed: strong operational results have been partly offset by investor concern over the approaching loss of exclusivity on dolutegravir, GSK's key HIV medicine, expected between 2028 and 2030. Shares have gained meaningfully over the trailing year but remain below their 52-week high.
JNJ Overview and Recent Performance
Johnson & Johnson is a diversified healthcare company spanning two segments: Innovative Medicine (pharmaceuticals) and Medical Technology (devices). In its most recent quarterly report, JNJ beat earnings expectations and raised full-year guidance, driven by pharmaceutical strength. Key growth drivers such as Tremfya, Darzalex, and newer oncology therapies delivered double-digit gains, helping offset a sharp decline in Stelara sales following biosimilar competition. The Medical Technology segment, by contrast, has grown more slowly, pressured by pricing dynamics in China, European spending constraints, and regional disruptions. JNJ continues to work through talc-related litigation, proposing a settlement to resolve remaining ovarian claims. The stock has rallied substantially over the past year, and analysts have maintained a broadly favorable consensus rating, though the valuation now reflects a premium to historical ranges.
Trending AI Robots
Tickeron's Trending AI Robots page curates the platform's most promising automated trading strategies for current market conditions. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only a select subset earns a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance history, statistics, and basket of tickers, so the tools available vary widely in approach and risk profile. This curated list is designed to help traders and investors quickly identify the strategies best suited to prevailing market dynamics rather than sifting through the full catalog. Exploring the Trending AI Robots section can offer a practical starting point for those interested in data-driven approaches to stock selection and timing.
Head-to-Head Comparison
The two companies differ most clearly in business model and diversification. GSK is concentrated in pharmaceuticals and vaccines, giving it higher sensitivity to drug-development outcomes and patent cycles but also a sharper growth profile in specialty areas. Johnson & Johnson's Medical Technology segment adds a device franchise that diversifies revenue but has recently acted as a drag on overall growth. In terms of growth drivers, GSK is leaning on oncology, respiratory, and HIV to reach its 2031 revenue ambition, while JNJ is building a large oncology and immunology portfolio to replace Stelara and aims to exceed $50 billion in oncology sales by 2030. On risk factors, GSK's most visible overhang is the dolutegravir patent cliff, whereas JNJ contends with litigation, slower MedTech execution, and a richer valuation. Market sentiment toward both has improved over the past year, but the relative positioning differs: GSK carries a lower earnings multiple and a higher dividend yield, while JNJ commands a premium valuation that leaves less margin for disappointment.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor the stock with the more consistent trend and clearer near-term catalyst set, while weighing relative valuation. GSK presents a steadier operational narrative with ongoing efficiency gains, a reaffirmed growth framework, and a comparatively attractive valuation, though it faces a well-telegraphed patent cliff. Johnson & Johnson offers stronger recent sales momentum and a deeper pipeline transformation, but its higher multiple and softer MedTech segment introduce greater execution risk. On balance, the AI's probabilistic assessment would lean toward GSK for its favorable combination of valuation, dividend support, and defined growth catalysts, while noting that JNJ's improving fundamentals could shift the picture as its new franchises scale.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Hold and JNJ is a Buy.
GSK in -1.60% downward trend, falling for three consecutive days on November 06, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GSK declined for three days, in 159 of 287 cases, the price declined further within the following month. The odds of a continued downward trend are 55%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GSK as a result. In 37 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 48%.
GSK broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GSK entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GSK's RSI Indicator exited the oversold zone, 15 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for GSK just turned positive on November 04, 2026. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in 30 of 46 cases over the following month. The odds of a continued upward trend are 65%.
GSK moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GSK crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Following a +3.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 202 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 35 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.715) is normal, around the industry mean (-1.360). P/E Ratio (20.988) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.036) settles around the average of (0.038) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).
JNJ in upward trend: 10-day moving average broke above 50-day moving average on October 30, 2026
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Indicator exited the oversold zone, 17 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 38 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 45%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 19 of 47 cases over the following month. The odds of a continued upward trend are 40%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 62 cases where JNJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.360). P/E Ratio (31.640) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
GSK | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 25 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 35 | 2 | |
SMR RATING 1..100 | 34 | 37 | |
PRICE GROWTH RATING 1..100 | 47 | 18 | |
P/E GROWTH RATING 1..100 | 8 | 6 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (75) in the Pharmaceuticals Major industry is in the same range as GSK (81). This means that JNJ’s stock grew similarly to GSK’s over the last 12 months.
JNJ's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (35). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
GSK's SMR Rating (34) in the Pharmaceuticals Major industry is in the same range as JNJ (37). This means that GSK’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Price Growth Rating (18) in the Pharmaceuticals Major industry is in the same range as GSK (47). This means that JNJ’s stock grew similarly to GSK’s over the last 12 months.
JNJ's P/E Growth Rating (6) in the Pharmaceuticals Major industry is in the same range as GSK (8). This means that JNJ’s stock grew similarly to GSK’s over the last 12 months.
| GSK | JNJ | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 65% | 1 day ago 59% |
| Stochastic ODDS (%) | 1 day ago 33% | 1 day ago 52% |
| Momentum ODDS (%) | 1 day ago 48% | 1 day ago 45% |
| MACD ODDS (%) | 1 day ago 65% | 1 day ago 40% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 47% |
| TrendMonth ODDS (%) | 1 day ago 59% | 1 day ago 50% |
| Advances ODDS (%) | 23 days ago 63% | 10 days ago 46% |
| Declines ODDS (%) | 1 day ago 55% | 5 days ago 43% |
| BollingerBands ODDS (%) | 1 day ago 42% | 1 day ago 41% |
| Aroon ODDS (%) | 1 day ago 46% | 1 day ago 44% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 1 FA rating(s) are green while JNJ’s FA Score has 3 green FA rating(s).
- GSK’s FA Score: 1 green, 4 red.
- JNJ’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 5 TA indicator(s) are bullish while JNJ’s TA Score has 6 bullish TA indicator(s).
- GSK’s TA Score: 5 bullish, 5 bearish.
- JNJ’s TA Score: 6 bullish, 4 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а +1.66% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +1.11% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.85%. For the same industry, the average monthly price growth was -1.19%, and the average quarterly price growth was +4.39%.
Reported Earning Dates
GSK is expected to report earnings on Feb 03, 2027.
JNJ is expected to report earnings on Jan 26, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-0.85% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.